Clinical trials · Philadelphia, PA
Lymphoma clinical trials in Philadelphia
We’re tracking 77 recruiting lymphoma studies with a site in or near Philadelphia — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT06137144RecruitingPhase 1/Phase 2
AZD3470 for lymphoma that has come back or not responded
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
Philadelphia, PennsylvaniaAges 12 years+ - NCT04094610RecruitingPhase 1/Phase 2
Repotrectinib for kids with certain cancer gene changes
This early-phase study tests repotrectinib, a targeted medicine, in children and young adults whose tumors have specific gene changes involving ROS1 or NTRK. It may help shrink advanced cancers that carry these gene alterations.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06337318RecruitingPhase 3
Comparing two drugs for low-tumor burden follicular lymphoma
This trial compares a standard drug called rituximab to a newer medicine called mosunetuzumab for people with a slow-growing type of lymphoma that is not causing many symptoms. The goal is to see if mosunetuzumab works better and has fewer side effects.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07586618RecruitingPhase 1
New Drug 4A10 for Hard-to-Treat Lymphoblastic Leukemia or Lymphoma
This is an early-stage study testing a new experimental drug (4A10) in patients whose acute lymphoblastic leukemia or lymphoblastic lymphoma has returned or stopped responding to standard treatments. Researchers want to learn if the drug is safe and how it works in the body.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Philadelphia, PennsylvaniaAges birth–18 years - NCT06500273RecruitingPhase 2
Cema-cel for high-risk lymphoma after first treatment
This trial tests a new treatment called cema-cel for people with large B-cell lymphoma who are in remission after first-line therapy but still have tiny amounts of cancer detected by a sensitive blood test. The goal is to prevent the cancer from coming back.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06395103RecruitingPhase 1/Phase 2
Zilovertamab vedotin for blood cancers and solid tumors
This trial tests a new drug called zilovertamab vedotin for children and young adults with certain blood cancers or solid tumors. The drug is designed to target and kill cancer cells, and the study will see if it is safe and effective.
Philadelphia, PennsylvaniaAges 6 months–25 years - NCT07188090RecruitingPhase 2
Mozobil for stem cell transplant study
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Philadelphia, PennsylvaniaAges 1–21 - NCT07220187RecruitingPhase 3
Adding pirtobrutinib to usual treatment for newly diagnosed Richter transformation
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Philadelphia, PennsylvaniaAges Any age - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Philadelphia, PennsylvaniaAges Any age - NCT07343934RecruitingPhase 1
CAR T-cell therapy for follicular lymphoma
This trial tests a new type of CAR T-cell therapy that may help people with follicular lymphoma that has come back or not responded to earlier treatments. The therapy uses your own immune cells, modified to recognize and attack the cancer cells.
Philadelphia, PennsylvaniaAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Philadelphia, PennsylvaniaAges Any age - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Philadelphia, PennsylvaniaAges 12 months–25 years - NCT06839456RecruitingPhase 1/Phase 2
Stem cell addback to prevent infections after transplant
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
Philadelphia, PennsylvaniaAges 1 month–25 years - NCT03011814RecruitingPhase 1/Phase 2
Durvalumab plus lenalidomide for relapsed T-cell lymphoma
This study tests a combination of two drugs—durvalumab (an immunotherapy) and lenalidomide (a targeted therapy)—to see if they are safe and effective for people with T-cell lymphoma that has come back or not responded to treatment. It aims to harness your immune system to fight the cancer while also attacking the cancer cells directly.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02693535RecruitingPhase 2
Targeted drug testing for advanced cancer with tumor gene changes
This trial tests whether FDA-approved targeted drugs can help people with advanced cancer whose tumors have specific gene changes. It aims to match your tumor's unique genetic profile to a drug that may work better for you.
Philadelphia, PennsylvaniaAges 12 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Lymphoma trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Lymphoma trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting lymphoma studies listed above.
- Children's Hospital of Philadelphia · 6 studies
- Thomas Jefferson University Hospital · 4 studies
- Fox Chase Cancer Center · 3 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
- Saint Christopher's Hospital for Children · 2 studies
- Thomas Jefferson University · 2 studies
- University of Pennsylvania · 2 studies
- University of Pennsylvania/Abramson Cancer Center · 2 studies
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lymphoma studies in Pennsylvania.
Common questions
- Are there lymphoma clinical trials near Philadelphia?
- Yes. We're currently tracking 77 recruiting lymphoma studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.